

ALZHEIMER'S DISEASE: TIME FOR CHANGE NOW

There is a need to **revolutionise the management of Alzheimer's Disease**. Lilly has dedicated over 30 years to supporting research efforts in Alzheimer's¹ and is **committed to being part of a better future** for people living with this devastating disease and their loved ones.

A GROWING GLOBAL HEALTH CRISIS

EVERY 3 SECONDS someone around the world develops dementia primarily as a result of **Alzheimer's disease**²

416 MILLION PEOPLE worldwide at risk of developing dementia caused by Alzheimer's⁴

>55 MILLION PEOPLE with dementia expected to be **~140 million by 2050**³

Annually dementia costs healthcare systems **~\$1 TRILLION** by 2030 expected to reach **>\$2.8 TRILLION**³

AFFECTING INDIVIDUALS AND FAMILIES

On average caregivers spend **5 HOURS A DAY** looking after a loved one with dementia,³ which can lead caregivers to experience:

-  - LOSS OF EARNINGS⁵
-  - SUBSTANTIAL FINANCIAL COSTS⁵
-  - INCREASED ANXIETY AND DEPRESSION⁵
-  - OTHER HEALTH ISSUES⁵

From the early stages of cognitive impairment, **ALZHEIMER'S LEADS TO SEVERE EMOTIONAL, SOCIAL, PSYCHOLOGICAL & PRACTICAL CHALLENGES** reducing life expectancy and independence^{6,7}



Half the global cost of dementia **-ROUGHLY \$500 BILLION-** is attributed to informal care³

Preventing or delaying cognitive decline relies on diagnosing and treating Alzheimer's disease earlier⁸


TODAY


As many as **75%** OF DEMENTIA CASES are undiagnosed²

Access to **ADVANCED DIAGNOSTIC TOOLS** is limited⁹

Only **50%** OF DIAGNOSIS occurs early enough for emerging therapies to be an option¹⁰

OBTAINING A TIMELY AND ACCURATE DIAGNOSIS CAN:

 Enable earlier access to treatment and support, and better management of co-morbid conditions¹¹

 Help those affected plan for the future and **maintain their quality of life and independence for longer**^{11,12}

 Offer people the chance to **participate in clinical trials**^{11,12}

Changing the course of Alzheimer's disease in the early stages can limit the damage caused and reduce the impact on individuals, loved ones and health services.

Lilly is calling for policies which:

- Encourage more people to **recognise the early signs** and seek help
- Arm clinicians with the tools to **diagnose earlier and more accurately**
- Address gaps in care pathways** to improve patient outcomes

GM-31058

Lilly

References

1. Eli Lilly and Company. Alzheimer's webpage. Available at: <https://www.lilly.com/disease-areas/alzheimers>. Last accessed August 2022
2. Alzheimer's Disease International. Dementia Statistics. Available at: <https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/>. Last accessed June 2022.
3. World Health Organization. Dementia. Available at: <https://www.who.int/news-room/fact-sheets/detail/dementia>. Last accessed June 2022.
4. Gustavsson, A, Norton, N, Fast, T, et al. Global estimates on the number of persons across the Alzheimer's disease continuum. *Alzheimer's Dement*. 2022; 1-13. <https://doi.org/10.1002/alz.12694>.
5. Lindeza P, et al. *BMJ Supportive & Palliative Care* 2020;0:1-12. doi:10.1136/bmjspcare-2020-002242.
6. Mayo Clinic. Alzheimer's disease. Available at: <https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers-stages/art-20048448>. Last accessed April 2022
7. Abbas A, Monfared T, Byrnes MJ. The Humanistic and Economic Burden of Alzheimer's Disease. *Neurol Ther*. 2002. doi.org/10.1007/s40120-022-00335-x
8. Biagioni MC, Galvin JE. Using biomarkers to improve detection of Alzheimer's disease. *Neurodegener Dis Manag*. 2011 Apr;1(2):127-139.
9. Waldemar G, et al. Access to diagnostic evaluation and treatment for dementia in Europe. *International Journal of Geriatric Psychiatry*. 2007; 22, 1. <https://doi.org/10.1002/gps.1652>
10. Kotagal V, et al. Factors Associated with Cognitive Evaluations in the United States. *Neurology* 2015;84(1):64-71
11. Rasmussen, J., & Langerman, H. (2019). Alzheimer's Disease - Why We Need Early Diagnosis. *Degenerative neurological and neuromuscular disease*, 9, 123-130. <https://doi.org/10.2147/DNND.S228939>.
12. Bradford A, Kunik ME, Schulz P, Williams SP, Singh H. Missed and delayed diagnosis of primary care: prevalence and contributing factors. *Alzheimer Dis Assoc Disord*. 2009 Oct-Dec;23(4):306-14.